Article
Give us your opinion on our latest poll, and see what your colleagues are saying. You can see the results of our previous surveys here as well.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
Experts share insights on next-generation NMIBC therapies
Study shows value of precision-based approaches in prostate cancer